<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-13T03:03:07Z</responseDate>
  <request identifier="oai:figshare.com:article/33983521" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/33983521</identifier>
        <datestamp>2026-09-24T12:22:47Z</datestamp>
        <setSpec>category_15</setSpec>
        <setSpec>portal_316</setSpec>
        <setSpec>item_type_3</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>Table 1_Minding the gates: dual cell-autonomous and non-cell-autonomous mechanisms of TBK1 in ALS/FTD.pdf</dc:title>
          <dc:creator>Julie Smeyers (20943075)</dc:creator>
          <dc:creator>Daniel A. Mordes (8399244)</dc:creator>
          <dc:subject>Neuroscience</dc:subject>
          <dc:subject>ALS</dc:subject>
          <dc:subject>FTD</dc:subject>
          <dc:subject>cell autonomous</dc:subject>
          <dc:subject>non-cell-autonomous</dc:subject>
          <dc:subject>in vivo models</dc:subject>
          <dc:subject>TBK1</dc:subject>
          <dc:description>&lt;p&gt;Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) comprise a neurodegenerative disease spectrum characterized by TDP-43 pathology and overlapping genetic risk factors. Loss-of-function variants in TBK1 (TANK-binding kinase 1) represent one of the most common genetic causes of ALS/FTD, highlighting haploinsufficiency for TBK1 as a major contributor to disease pathogenesis. Emerging evidence from iPSC and mouse models suggests that reduced TBK1 activity disrupts interconnected autophagy, endo-lysosomal, and innate immune pathways through both cell-autonomous and non-cell-autonomous mechanisms. In this review, we discuss the multifaceted role of TBK1 as a master regulator of proteostasis and inflammatory pathways, highlight its critical role in maintaining microglial homeostasis, and explore how these convergent functions inform therapeutic strategies for ALS/FTD.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-24T12:22:47Z</dc:date>
          <dc:type>Dataset</dc:type>
          <dc:type>Dataset</dc:type>
          <dc:identifier>10.3389/fnins.2026.1941293.s001</dc:identifier>
          <dc:relation>https://figshare.com/articles/dataset/Table_1_Minding_the_gates_dual_cell-autonomous_and_non-cell-autonomous_mechanisms_of_TBK1_in_ALS_FTD_pdf/33983521</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
